

# METHOD AND KIT TO PREDICT SURVIVAL OF PATIENTS SUFFERING FROM MANTLE CELL LYMPHOMA

*The present invention relates to a method for diagnosis and prognosis of mantle cell lymphoma based on quantitative gene-expression of five selected genes, applicable in a routine diagnostic and with higher capacity of survival prediction than current methods.*

## BACKGROUND

Mantle cell lymphoma (MCL) is a distinctive subtype of B-cell non-Hodgkin's lymphoma characterized by the translocation t(11;14) (q13,32) and the overexpression of Cyclin D1.

In general, MCL shows an aggressive clinical behavior with poor response to current therapeutic approaches, and the median survival of MCL patients following diagnosis is between 3 and 5 years. However, some patients succumb to their disease in less than 6 month, while others survive more than 10 years. The current treatment approaches for MCL patients are rather uniform and rarely reflect the widely varying clinical behavior.

In recent years, many attempts have been made to stratify MCL patients into different risk groups. However, the current prognosis indicator Ki-67 (measured by immunohistochemistry) is highly dependent of pathologist interpretation and does not fulfill the clinical and investigational requirements.

## TECHNOLOGY DESCRIPTION

Accurate and quantitative method to predict the survival of patients with MCL by measuring the expression of 5 selected genes.

## ADVANTAGES

- The test is applicable in the routine diagnostic using both frozen and formalin-fixed paraffin-embedded samples.
- It discriminates better the survival of the patients . It is more objective than the

immunohistochemical measurement of the Ki-67 index).

- As the method determines how aggressive the lymphoma is, more individualized and risk-adapted treatment strategies can be tested in prospective clinical trials.

## CURRENT STAGE OF DEVELOPMENT

Validation of the method with more samples of MCL patients.

## GOAL

We are searching companies interested in the acquisition of the license, the development of the kit and its commercialization.

## PATENT

A patent application with number P200703071 was filed on November 2007 by the University of Barcelona and a PCT was extended one year later.

## CONTACT

Mireia Angulo  
Fundació Clínic  
Tel. + 34 (93) 2275400 (ext. 4354)  
[mangulo@clinic.ub.es](mailto:mangulo@clinic.ub.es)